FinancialContent

Articles published by Chemomab Therapeutics

News headline image
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Announces New Medical and Clinical Appointments
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics to Present at October 2024 Investor Conferences
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics to Present at September 2024 Investor Conferences
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics Announces $10 Million Private Placement
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB
News headline image
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Tickers CMMB